N4P has released an update on its ongoing work programmes.
TPI provides its latest research note on N4 Pharma plc (N4P.L).
N4 Pharma PLC (N4P.L) Operational Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide the following update on its ongoing
N4 Pharma PLC (N4PL) Covid-19 Proof of Concept Update
Covid-19 Proof of Concept Update and move to in vivo study
TPI provides its latest research note on N4 Pharma plc (N4P.L).
N4P has announced the appointment of Ardena Holding NV (‘Ardena’) as its contract development and manufacturing organisation (‘CDMO’) partner for the technology transfer and upscaling manufacture of Nuvec®, the Group’s unique silica nanoparticle
N4 Pharma PLC (N4P.L) Technology Transfer and Manufacturing Contract
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing, a novel delivery system for cancer treatments and vaccines, announces that it has appointed the API and Nanomedicines business unit
N4 Pharma PLC (AIM:N4P) Filing of Patents and Sildenafil Update
N4 Pharma Plc (AIM: N4P), a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, is pleased to announce the filing of its Patent Cooperation Treaty
